Targeting KRAS Mutant Lung Cancers Dream Team - Stand Up To Cancer

Dream Teams

Research  >  Research Portfolio  >  Dream Teams  >  Targeting KRAS Mutant Lung Cancers Dream Team

SU2C–American Cancer Society Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers

Grant Term: August 2015–July 2019

The SU2C–American Cancer Society (ACS) Lung Cancer Dream Team has established a collaborative, scientifically rigorous, multidisciplinary program that brings together two highly promising treatment approaches: targeted therapy―in this case targeting the KRAS gene―and immunotherapy. This combined approach should lead to novel treatments that will markedly improve outcomes for KRAS-mutant non-small cell lung cancer patients.


Mutations in the KRAS gene are found in 20 to 25% of lung cancers. These cancers do not respond well to standard lung cancer treatments and are notoriously difficult to treat. Scientists are working to develop new drugs that specifically target biological pathways disrupted by the mutant KRAS gene.

The goal of the SU2C–ACS Lung Cancer Dream Team has been to develop and bring together these two highly promising therapeutic approaches of targeted therapy and immunotherapy: combining types of therapies and also working to predict which patients will benefit from the therapy.

The team is currently conducting a myriad of clinical trials, including trials combining targeted therapies called MEK inhibitors with checkpoint inhibitors. MEK inhibitors modulate overactive cellular signaling pathways while checkpoint inhibitors block the function of the PD-1 receptor, a protein on cell surfaces that inhibits normal immune response. To maximize the benefit of immunotherapy, the team is also analyzing samples from patients who have been treated with immune checkpoint inhibitors. The team seeks to identify ways to predict which patients are more likely to respond to immunotherapy.


Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.